EDGAR Filing Documents for 0001193125-20-036662

Form 8-K - Current report:

SEC Accession No. 0001193125-20-036662

Filing Date

2020-02-14

Accepted

2020-02-14 07:17:03

Documents

Period of Report

2020-02-14

Items

Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	d885103d8k.htm	8-K	25331
2	EX-3.1	d885103dex31.htm	EX-3.1	77600
3	EX-99.1	d885103dex991.htm	EX-99.1	17892
4	EX-99.2	d885103dex992.htm	EX-99.2	10368
5	EX-99.3	d885103dex993.htm	EX-99.3	11610
6	EX-99.4	d885103dex994.htm	EX-99.4	9124
7	EX-99.5	d885103dex995.htm	EX-99.5	16722
8	EX-99.6	d885103dex996.htm	EX-99.6	13347
9	EX-99.7	d885103dex997.htm	EX-99.7	21428
10	EX-99.8	d885103dex998.htm	EX-99.8	8001
11	GRAPHIC	g885103g96e29.jpg	GRAPHIC	413741
12	GRAPHIC	g885103img1.jpg	GRAPHIC	11188
	Complete submission text file	0001193125-20-036662.txt		798429

Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121

Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100

CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)